Avidus Publishes White Paper on Asantae IS2™ Inflammation & Immune Support Supplement

VANCOUVER, BC and MESA, AZ, Jan. 9, 2014 /PRNewswire/ - Avidus Management Group Inc. ("Avidus" or the "Company") (TSX-V: AVD, OTC: ASNHF), announces that its wholly owned subsidiary, Asantae, has published a White Paper on IS2™, its revolutionary inflammation and immune support functional beverage.  The paper, by Dwight Lundell, M.D., is titled, The Science of Inflammation & Immunity.

IS2™ is a proprietary blend of unique ingredients synergistically combined to support a proper immune and inflammatory response.

The White Paper details how 60 percent of the deaths worldwide today are from non-communicable diseases (e.g. heart disease, stroke, obesity, diabetes) and that the common pathology in all these diseases, as well as in less dramatic conditions that plague humankind (e.g. chronic pain, fibromyalgia, osteoarthritis), is inflammation.  The document also explores how the ingredients found in IS2™ are shown to aid in resolving inflammation by strengthening the body's natural immune system and inflammatory processes.

• The IS2™ White Paper can be accessed at: http://www.asantae.com/documents/the_science_of_is2.pdf
• A brief video presentation about IS2™ and inflammation can be viewed at: http://vimeo.com/76877186
  
  

Launched in October 2013, IS2™ is generating positive feedback from Asantae's customers and distributors and has enabled the company to attract top network marketers from other well-established companies.

About Avidus

Avidus Management Group Inc. (TSX-V: AVD, OTC: ASNHF), through its wholly owned subsidiary, Asantae (www.asantae.com), develops, produces and markets innovative nutritional products through direct and network marketing channels. The ingredients in Asantae's products have been shown to reduce chronic low-grade inflammation and oxidative stress, and support a healthy immune system that, according to scientific and medical research, are the underlying conditions for most modern epidemic diseases (diabetes, heart disease, obesity, stroke, etc.). 

This news release may contain forward-looking statements relating to the Company's operations or to the environment in which it operates. Such statements are based on operations, estimates, forecasts and projections. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and may be beyond the Company's control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements, including those set forth in the Company's regulatory filings. In addition, such statements relate to the date on which they are made and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, save and except as may be required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Avidus Management Group Inc.